Literature DB >> 20675744

Front-line treatment of mantle cell lymphoma.

Christian H Geisler.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20675744      PMCID： PMC2913070          DOI： 10.3324/haematol.2010.025627

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  21 in total

1.  Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network.

Authors:  Martin Dreyling; Georg Lenz; Eva Hoster; Achiel Van Hoof; Christian Gisselbrecht; Rudolf Schmits; Bernd Metzner; Lorenz Truemper; Marcel Reiser; Hjalmar Steinhauer; Jean-Michel Boiron; Marc A Boogaerts; Ali Aldaoud; Vittorio Silingardi; Hanneke C Kluin-Nelemans; Joerg Hasford; Reza Parwaresch; Michael Unterhalt; Wolfgang Hiddemann
Journal:  Blood       Date:  2004-12-09       Impact factor: 22.113

2.  High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine.

Authors:  Jorge E Romaguera; Luis Fayad; Maria A Rodriguez; Kristine R Broglio; Frederick B Hagemeister; Barbara Pro; Peter McLaughlin; Anas Younes; Felipe Samaniego; Andre Goy; Andreas H Sarris; Nam H Dang; Michael Wang; Virginia Beasley; L Jeffrey Medeiros; Ruth L Katz; Harish Gagneja; Barry I Samuels; Terry L Smith; Fernando F Cabanillas
Journal:  J Clin Oncol       Date:  2005-09-06       Impact factor: 44.544

3.  Multicentre randomized therapeutic trial for advanced centrocytic lymphoma: anthracycline does not improve the prognosis.

Authors:  P Meusers; M Engelhard; H Bartels; T Binder; H H Fülle; K Görg; U Gunzer; K Havemann; W Kayser; E König
Journal:  Hematol Oncol       Date:  1989 Sep-Oct       Impact factor: 5.271

4.  Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG).

Authors:  Georg Lenz; Martin Dreyling; Eva Hoster; Bernhard Wörmann; Ulrich Dührsen; Bernd Metzner; Hartmut Eimermacher; Andreas Neubauer; Hannes Wandt; Hjalmar Steinhauer; Sonja Martin; Else Heidemann; Ali Aldaoud; Reza Parwaresch; Joerg Hasford; Michael Unterhalt; Wolfgang Hiddemann
Journal:  J Clin Oncol       Date:  2005-01-24       Impact factor: 44.544

5.  Sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell lymphoma: a prospective study.

Authors:  F Lefrère; A Delmer; F Suzan; V Levy; C Belanger; M Djabarri; B Arnulf; G Damaj; N Maillard; V Ribrag; M Janvier; C Sebban; R-O Casasnovas; R Bouabdallah; F Dreyfus; V Verkarre; E Delabesse; F Valensi; E McIntyre; N Brousse; B Varet; O Hermine
Journal:  Leukemia       Date:  2002-04       Impact factor: 11.528

6.  Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival.

Authors:  Orion M Howard; John G Gribben; Donna S Neuberg; Michael Grossbard; Christina Poor; Milos J Janicek; Margaret A Shipp
Journal:  J Clin Oncol       Date:  2002-03-01       Impact factor: 44.544

7.  EPOCH chemotherapy: toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma.

Authors:  W H Wilson; G Bryant; S Bates; A Fojo; R E Wittes; S M Steinberg; D R Kohler; E S Jaffe; J Herdt; B D Cheson
Journal:  J Clin Oncol       Date:  1993-08       Impact factor: 44.544

8.  Primary treatment with autologous stem cell transplantation in mantle cell lymphoma: outcome related to remission pretransplant.

Authors:  Niels S Andersen; Lone Pedersen; Erkki Elonen; Anna Johnson; Arne Kolstad; Kaarle Franssila; Ruth Langholm; Elisabeth Ralfkiaer; Måns Akerman; Mikael Eriksson; Outi Kuittinen; Christian H Geisler
Journal:  Eur J Haematol       Date:  2003-08       Impact factor: 2.997

9.  The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group.

Authors:  Roswitha Forstpointner; Martin Dreyling; Roland Repp; Sandra Hermann; Annette Hänel; Bernd Metzner; Christiane Pott; Frank Hartmann; Frank Rothmann; Robert Rohrberg; Hans-Peter Böck; Hannes Wandt; Michael Unterhalt; Wolfgang Hiddemann
Journal:  Blood       Date:  2004-07-29       Impact factor: 22.113

10.  A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma.

Authors:  Eva Hoster; Martin Dreyling; Wolfram Klapper; Christian Gisselbrecht; Achiel van Hoof; Hanneke C Kluin-Nelemans; Michael Pfreundschuh; Marcel Reiser; Bernd Metzner; Hermann Einsele; Norma Peter; Wolfram Jung; Bernhard Wörmann; Wolf-Dieter Ludwig; Ulrich Dührsen; Hartmut Eimermacher; Hannes Wandt; Joerg Hasford; Wolfgang Hiddemann; Michael Unterhalt
Journal:  Blood       Date:  2007-10-25       Impact factor: 22.113
View more
  2 in total

1.  Modified DHAP regimen in the salvage treatment of refractory or relapsed lymphomas.

Authors:  Frank Kroschinsky; Denise Röllig; Barbara Riemer; Michael Kramer; Rainer Ordemann; Johannes Schetelig; Martin Bornhäuser; Gerhard Ehninger; Mathias Hänel
Journal:  J Cancer Res Clin Oncol       Date:  2019-09-28       Impact factor: 4.553

Review 2.  The B cell receptor signaling pathway in mantle cell lymphoma.

Authors:  Maria I Merolle; Makhdum Ahmed; Krystle Nomie; Michael L Wang
Journal:  Oncotarget       Date:  2018-03-27
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.